Prostac™: Precise, Early and Non-Invasive Screening for Prostate Cancer

Pre-FDA approved, Prostac™ is a game-changing molecular-based blood test for the precise and early detection** of prostate cancer.  From blood drawn at the Doctor's office, Prostac™: ​

​

• Detects prostate cancer in men who have an elevated or higher PSA test score.

​​

• Detects prostate cancer in men who show symptoms of prostate cancer (blood in urine or semen, rapid weight loss, incontinence).   

​​

• Screens for a man's genetic predisposition to developing prostate cancer.

​

• ​Classifies the diagnosed prostate cancer into distinct risk groups ranging from indolent to aggressive castration-resistant.

​​

• Assists physicians in making better treatment decisions.

 
 
 
 
 

 

 

Men of African ancestry and men who have a family history of prostate cancer have a greater likelihood (i.e. a predisposition) of developing the disease, as are individuals in certain occupational settings. Prostac™ can be used to test these men so that they know with confidence their likelihood of developing or not developing prostate cancer.  
​
Men who have tested with a higher PSA score or who have a previous prostate cancer diagnosis can use Prostac™ to verify a prostate cancer diagnosis.  Men testing negative with Prostac™ could then avoid the expensive, intrusive and often harmful screening tests, and even more expensive and potentially life-damaging overtreatments. Prostac™ can also test men for the effectiveness of their treatments for prostate cancer.

Prostac™ takes away the worry and stress of an uncertain prostate cancer diagnosis and gives men the peace of mind and the confidence to take control of their personal health and well-being.   

** Note: In preliminary data analysis, Prostac™ is a better predictor of prostate cancer than PSA with better specificity, sensitivity and accuracy.